Clinical Trial: Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07688356) titled 'Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors' on June 25.

Brief Summary: This is a Phase 2, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Belvarafenib in patients with BRAF-altered primary brain tumors (Cohort 1) and metastatic brain tumors (Cohort 2). Eligible patients are those with a confirmed BRAF alteration identified by next-generation sequencing (NGS).

Patients who meet the eligibility criteria will receive a detailed explanation of the study, including its purpose, procedures, potential benefits, and risks. Only patients who voluntarily provide written infor...